Ivana Lagreca
Overview
Explore the profile of Ivana Lagreca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bettelli F, Vallerini D, Lagreca I, Barozzi P, Riva G, Nasillo V, et al.
PLoS One
. 2024 Jul;
19(7):e0306728.
PMID: 38980880
Objective: We investigated the performance of enzyme linked immunospot (ELISpot) assay for the diagnosis of invasive aspergillosis (IA) in high-risk patients with hematologic malignancies. Methods: We prospectively enrolled two cohorts...
2.
Mutti M, Cordella S, Parisotto A, Bettelli F, Morselli M, Cuoghi A, et al.
Leuk Lymphoma
. 2023 Dec;
65(4):511-515.
PMID: 38112426
No abstract available.
3.
De Cicco M, Lagreca I, Basso S, Barozzi P, Muscianisi S, Bianco A, et al.
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345068
Acute myeloid leukemia (AML) with nucleophosmin () genetic mutations is the most common subtype in adult patients. Refractory or relapsed disease in unfit patients or after allogeneic hematopoietic stem cell...
4.
Lagreca I, Nasillo V, Barozzi P, Castelli I, Basso S, Castellano S, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765928
Multiple Myeloma (MM) typically originates from underlying precursor conditions, known as Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM). Validated risk factors, related to the main features...
5.
Maffei R, Fiorcari S, Atene C, Martinelli S, Mesini N, Pilato F, et al.
Clin Exp Med
. 2022 Dec;
23(4):1171-1180.
PMID: 36495369
The trajectory of B cell development goes through subsequent steps governed by complex genetic programs, strictly regulated by multiple transcription factors. Interferon regulatory factor 4 (IRF4) regulates key points from...
6.
Barbieri E, Maccaferri M, Leonardi G, Giacobbi F, Corradini G, Lagreca I, et al.
Ann Hematol
. 2022 Sep;
101(12):2777-2779.
PMID: 36104630
No abstract available.
7.
Lagreca I, Riva G, Nasillo V, Barozzi P, Castelli I, Basso S, et al.
Int J Mol Sci
. 2022 May;
23(9).
PMID: 35563634
Multiple Myeloma (MM) is a malignant growth of clonal plasma cells, typically arising from asymptomatic precursor conditions, namely monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). Profound immunological...
8.
Nasillo V, Lagreca I, Vallerini D, Barozzi P, Riva G, Maccaferri M, et al.
Cells
. 2022 Mar;
11(6).
PMID: 35326454
In recent years, the introduction of new drugs targeting Bruton's tyrosine kinase (BTK) has allowed dramatic improvement in the prognosis of patients with chronic lymphocytic leukemia (CLL) and other B-cell...
9.
Galassi L, Colasante C, Bettelli F, Gilioli A, Pioli V, Giusti D, et al.
Leuk Res
. 2021 Nov;
111:106747.
PMID: 34781054
No abstract available.
10.
Riva G, Nasillo V, Ottomano A, Bergonzini G, Paolini A, Forghieri F, et al.
Cancers (Basel)
. 2021 Sep;
13(18).
PMID: 34572809
Along with the evolution of immunophenotypic and molecular diagnostics, the assessment of Minimal Residual Disease (MRD) has progressively become a keystone in the clinical management of hematologic malignancies, enabling valuable...